Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. The company was founded in 1850 and is headquartered in Durban, South Africa.
Revenue of Aspen Pharmacare Holdings Limited (APN.JO)
Revenue in 2023 (TTM): $44.71 B
According to Aspen Pharmacare Holdings Limited's latest financial reports the company's current revenue (TTM) is $44.71 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Aspen Pharmacare Holdings Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $44.71 B | $19.42 B | $9.91 B | $5.71 B | $4.4 B |
| 2022 | $40.71 B | $18.41 B | $9.5 B | $6.56 B | $5.23 B |
| 2021 | $38.61 B | $18.31 B | $10.48 B | $8.13 B | $6.49 B |
| 2020 | $37.77 B | $17.79 B | $8.67 B | $5.99 B | $4.81 B |
| 2019 | $38.65 B | $19.33 B | $7.27 B | $5.6 B | $4.66 B |
| 2018 | $38.87 B | $19.7 B | $5.54 B | $2.77 B | $6.46 B |
| 2017 | $42.6 B | $21.61 B | $9.82 B | $7.4 B | $6.01 B |
| 2016 | $41.2 B | $19.9 B | $9.5 B | $6.2 B | $5.1 B |
| 2015 | $35.6 B | $17.9 B | $9.4 B | $6.1 B | $4.3 B |
| 2014 | $36.13 B | $17.25 B | $9.53 B | $6.54 B | $5.2 B |
| 2013 | $29.52 B | $13.72 B | $8.64 B | $6.36 B | $5.01 B |
| 2012 | $19.31 B | $9.23 B | $5.61 B | $4.49 B | $3.52 B |
| 2011 | $15.26 B | $7.28 B | $4.19 B | $3.44 B | $2.82 B |
| 2010 | $12.38 B | $5.61 B | $3.73 B | $2.74 B | $2.59 B |
| 2009 | $10.15 B | $4.6 B | $2.98 B | $2.24 B | $1.98 B |
| 2008 | $8.45 B | $3.89 B | $2.62 B | $1.7 B | $1.35 B |
| 2007 | $4.88 B | $2.22 B | $1.23 B | $1.21 B | $864.48 M |
| 2006 | $4.03 B | $1.94 B | $1.08 B | $1.01 B | $717.67 M |
| 2005 | $3.45 B | $1.66 B | $894.74 M | $854.68 M | $638.09 M |
| 2004 | $2.87 B | $1.39 B | $493.42 M | $702.91 M | $493.99 M |
| 2003 | $2.2 B | $1.06 B | $553.76 M | $528.47 M | $355.58 M |
| 2002 | $1.9 B | $860.84 M | $446.85 M | $388.91 M | $273.41 M |